Bill · H.R. 1244· House(119-HR-1244)
Reducing Drug Prices for Seniors Act
- Introduced
- 2/12/2025
- Last activity
- 2/12/2025 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Donald Davis
- Cosponsors
- - 1 - 1
- Introduced
- In Committee
What this bill would do
This bill, known as the "Reducing Drug Prices for Seniors Act," seeks to amend the Social Security Act regarding Medicare Part D. It changes how coinsurance is calculated for covered drugs. Instead of using the wholesale acquisition cost, the bill requires coinsurance to be based on the drug's actual acquisition cost when that cost is lower. This change would apply to plan years starting on or after January 1, 2026. The actual acquisition cost is defined as the negotiated price net of any manufacturer-provided price concessions.
Yes· 3 of 14
Would people over 65 be better off under this?+7
The bill directly lowers out-of-pocket prescription drug costs for seniors through the Medicare Part D program.
Would retired people be better off under this?+7
The bill lowers the cost of prescription drugs for retirees enrolled in Medicare Part D.
Does this lower the price of prescription medicines?+7
The bill reduces out-of-pocket drug costs for seniors by calculating coinsurance based on the drug's actual acquisition cost rather than the higher wholesale price.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Lower Coinsurance Amounts: For plan years beginning on or after January 1, 2026, coinsurance for covered Part D drugs will be calculated based on the actual acquisition cost if it is lower than the wholesale acquisition cost. This is considered positive because it changes the basis of the calculation for costs above the annual deductible and below the out-of-pocket threshold. (Section 2, subsection (b)(10)(A))
-
Clearer Definition of Cost: The bill defines "actual acquisition cost" as the negotiated price of the drug under the plan, net of any manufacturer-provided price concessions, as reported in the Detailed DIR Report. (Section 2, subsection (b)(10)(B))
Potential Negative Impacts for People
- No negative impacts are explicitly stated in the text provided.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Retirees+7Good For Seniors+7Good For Low Income Households+3Good For African Americans+2Good For Asian Americans+2Good For Hispanic Americans+2Good For Middle Class Households+2Good For Native Americans+2Good For White Americans+2
- Healthcare
- Reduces Prescription Drug Costs+7Improves Healthcare Access+2Increases Medicare Funding+1
- Social Issues And Justice
- Improves Social Security+2
- Economy And Finance
- Improves Economic Growth+1
- 10/17/2025
- 1 Cosponsor added.
- 2/12/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 1 Cosponsor added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Josh HarderDemocrat · California
August PflugerRepublican · Texas